BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 17384213)

  • 1. Absence of RET gene point mutations in sporadic thyroid C-cell hyperplasia.
    Saggiorato E; Rapa I; Garino F; Bussolati G; Orlandi F; Papotti M; Volante M
    J Mol Diagn; 2007 Apr; 9(2):214-9. PubMed ID: 17384213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients.
    Guyétant S; Josselin N; Savagner F; Rohmer V; Michalak S; Saint-André JP
    Mod Pathol; 2003 Aug; 16(8):756-63. PubMed ID: 12920219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2.
    Moore SW; Appfelstaedt J; Zaahl MG
    J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rare RET gene exon 8 mutation is found in two Greek kindreds with familial medullary thyroid carcinoma: implications for screening.
    Kaldrymides P; Mytakidis N; Anagnostopoulos T; Vassiliou M; Tertipi A; Zahariou M; Rampias T; Koutsodontis G; Konstantopoulou I; Ladopoulou A; Bei T; Yannoukakos D
    Clin Endocrinol (Oxf); 2006 May; 64(5):561-6. PubMed ID: 16649977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary/papillary thyroid carcinomas in 2 large, non-related families with the RET V804M proto-oncogene mutation.
    Shifrin AL; Ogilvie JB; Stang MT; Fay AM; Kuo YH; Matulewicz T; Xenachis CZ; Vernick JJ
    Surgery; 2010 Dec; 148(6):1274-80; discussion 1280-1. PubMed ID: 21134561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma.
    Weinhaeusel A; Scheuba C; Lauss M; Kriegner A; Kaserer K; Vierlinger K; Haas OA; Niederle B
    Thyroid; 2008 Dec; 18(12):1269-76. PubMed ID: 18976163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RET mutation status in medullary thyroid cancer(MTC) patients and the significance of genetic screening for mutations in their immediate relatives--a preliminary report.
    Menon MM; Simha MR
    Indian J Pathol Microbiol; 2005 Apr; 48(2):161-5. PubMed ID: 16758654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathological and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia?
    Verga U; Ferrero S; Vicentini L; Brambilla T; Cirello V; Muzza M; Beck-Peccoz P; Fugazzola L
    Endocr Relat Cancer; 2007 Jun; 14(2):393-403. PubMed ID: 17639053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma.
    Cordella D; Muzza M; Alberti L; Colombo P; Travaglini P; Beck-Peccoz P; Fugazzola L; Persani L
    Endocr Relat Cancer; 2006 Sep; 13(3):945-53. PubMed ID: 16954442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels.
    Milone F; Ramundo V; Chiofalo MG; Severino R; Paciolla I; Pezzullo L; Lombardi G; Colao A; Faggiano A
    Clin Endocrinol (Oxf); 2010 Jul; 73(1):85-8. PubMed ID: 20039894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mutations of ret-proto-oncogene in thyroid medullary carcinoma].
    Frank-Raue K; Höppner W; Buhr H; Herfarth C; Ziegler R; Raue F
    Dtsch Med Wochenschr; 1997 Feb; 122(6):143-9. PubMed ID: 9081799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.
    Rodríguez-Antona C; Muñoz-Repeto I; Inglada-Pérez L; de Cubas AA; Mancikova V; Cañamero M; Maliszewska A; Gómez A; Letón R; Leandro-García LJ; Comino-Méndez I; Sanchez L; Alvarez-Escolá C; Aller J; Cascón A; Robledo M
    Endocr Relat Cancer; 2013 Aug; 20(4):611-9. PubMed ID: 23780998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways.
    Ameur N; Lacroix L; Roucan S; Roux V; Broutin S; Talbot M; Dupuy C; Caillou B; Schlumberger M; Bidart JM
    Endocr Relat Cancer; 2009 Dec; 16(4):1261-72. PubMed ID: 19675075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Succinate dehydrogenase D variants do not constitute a risk factor for developing C cell hyperplasia or sporadic medullary thyroid carcinoma.
    Cascon A; Cebrian A; Pollan M; Ruiz-Llorente S; Montero-Conde C; Leton R; Gutierrez R; Lesueur F; Milne RL; Gonzalez-Albarran O; Lucas-Morante T; Benitez J; Ponder BA; Robledo M
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2127-30. PubMed ID: 15623805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ["Physiological" and "neoplastic" C-cell hyperplasia of the thyroid. Morphologically and biologically distinct entities?].
    Hinze R; Gimm O; Brauckhoff M; Schneyer U; Dralle H; Holzhausen HJ
    Pathologe; 2001 Jul; 22(4):259-65. PubMed ID: 11490939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer.
    Romei C; Ugolini C; Cosci B; Torregrossa L; Vivaldi A; Ciampi R; Tacito A; Basolo F; Materazzi G; Miccoli P; Vitti P; Pinchera A; Elisei R
    Thyroid; 2012 May; 22(5):476-81. PubMed ID: 22404432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polysialic acid of the neural cell adhesion molecule in the human thyroid: a marker for medullary thyroid carcinoma and primary C-cell hyperplasia. An immunohistochemical study on 79 thyroid lesions.
    Komminoth P; Roth J; Saremaslani P; Matias-Guiu X; Wolfe HJ; Heitz PU
    Am J Surg Pathol; 1994 Apr; 18(4):399-411. PubMed ID: 8141431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-cell hyperplasia in sporadic and familial medullary thyroid carcinoma.
    Yadav M; Agrawal V; Pani KC; Verma R; Jaiswal S; Mishra A; Pandey R
    Indian J Pathol Microbiol; 2018; 61(4):485-488. PubMed ID: 30303134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidental thyroid C cell hyperplasia: clinical significance and implications in practice.
    Sakorafas GH; Nasikas D; Thanos D; Gantzoulas S
    Oncol Res Treat; 2015; 38(5):249-52. PubMed ID: 25966772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.